BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37422608)

  • 21. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of EORTC QLQ-C30 and PRO-CTCAE™ Questionnaires on Six Symptom Items.
    Taarnhøj GA; Kennedy FR; Absolom KL; Bæksted C; Vogelius IR; Johansen C; Velikova G; Pappot H
    J Pain Symptom Manage; 2018 Sep; 56(3):421-429. PubMed ID: 29807157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
    J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Developing tumor-specific PRO-CTCAE item sets: analysis of a cross-sectional survey in three German outpatient cancer centers.
    Günther M; Hentschel L; Schuler M; Müller T; Schütte K; Ko YD; Schmidt-Wolf I; Jaehde U
    BMC Cancer; 2023 Jul; 23(1):629. PubMed ID: 37407982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
    Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
    J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E; Becker C; Rogak LJ; Schrag D; Reeve BB; Spears P; Smith ML; Gounder MM; Mahoney MR; Schwartz GK; Bennett AV; Mendoza TR; Cleeland CS; Sloan JA; Bruner DW; Schwab G; Atkinson TM; Thanarajasingam G; Bertagnolli MM; Dueck AC
    Clin Trials; 2021 Feb; 18(1):104-114. PubMed ID: 33258687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translation Into Simplified Chinese and Cultural Validation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Using Cognitive Interviewing.
    Shen N; Ruan H; Sun J; Li Y; He M; Yuan C; Chang L
    Cancer Nurs; 2023 Jan-Feb 01; 46(1):E31-E40. PubMed ID: 35583994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptomatic adverse events of chemotherapy in breast cancer patients:Using CTCAE, PRO-CTCAE, and EORTC QLQ-C30.
    Arahori H; Kondo K; Imai Y; Bando T; Inoue H; Sasa S; Takizawa H
    J Med Invest; 2024; 71(1.2):82-91. PubMed ID: 38735729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
    Taarnhøj GA; Johansen C; Lindberg H; Basch E; Dueck A; Pappot H
    Cancer Med; 2020 May; 9(9):3078-3087. PubMed ID: 32154663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surveillance of Symptom Burden Using the Patient-Reported Outcome Version of the Common Terminology Criteria for Adverse Events in Patients With Various Types of Cancers During Chemoradiation Therapy: Real-World Study.
    Kang D; Kim S; Kim H; Lee M; Kong SY; Chang YJ; Sim SH; Kim YJ; Cho J
    JMIR Public Health Surveill; 2023 Mar; 9():e44105. PubMed ID: 36884274
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of patient-reported outcomes (PRO) data to complement exposure-response analysis in early clinical cancer drug development.
    Xia H; Booth BP; Wang Y; Fan C; Bhatnagar V; Kluetz P; Fourie Zirkelbach J
    J Patient Rep Outcomes; 2023 Nov; 7(1):116. PubMed ID: 37975967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Kluetz PG; Chingos DT; Basch EM; Mitchell SA
    Am Soc Clin Oncol Educ Book; 2016; 35():67-73. PubMed ID: 27249687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients.
    Baeksted C; Pappot H; Nissen A; Hjollund NH; Mitchell SA; Basch E; Bidstrup PE; Dalton SO; Johansen C
    J Patient Rep Outcomes; 2017; 1(1):1. PubMed ID: 29757324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2.
    Mazza GL; Petersen MM; Ginos B; Langlais BT; Heon N; Gounder MM; Mahoney MR; Zoroufy AJ; Schwartz GK; Rogak LJ; Thanarajasingam G; Basch E; Dueck AC
    Qual Life Res; 2022 Apr; 31(4):1069-1080. PubMed ID: 34420143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linking the European Organisation for Research and Treatment of Cancer Item Library to the Common Terminology Criteria for Adverse Events.
    Gilbert A; Piccinin C; Velikova G; Groenvold M; Kuliś D; Blazeby JM; Bottomley A
    J Clin Oncol; 2022 Nov; 40(32):3770-3780. PubMed ID: 35973158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial.
    Basch E; Pugh SL; Dueck AC; Mitchell SA; Berk L; Fogh S; Rogak LJ; Gatewood M; Reeve BB; Mendoza TR; O'Mara AM; Denicoff AM; Minasian LM; Bennett AV; Setser A; Schrag D; Roof K; Moore JK; Gergel T; Stephans K; Rimner A; DeNittis A; Bruner DW
    Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):409-418. PubMed ID: 28463161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.